Equities analysts expect that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will report earnings of ($0.23) per share for the current quarter, according to Zacks. Two analysts have made estimates for Celldex Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.34) and the highest estimate coming in at ($0.19). Celldex Therapeutics posted earnings of ($0.30) per share during the same quarter last year, which would suggest a positive year over year growth rate of 23.3%. The business is scheduled to report its next earnings results on Tuesday, March 13th.
On average, analysts expect that Celldex Therapeutics will report full year earnings of ($0.93) per share for the current year, with EPS estimates ranging from ($1.06) to ($0.86). For the next fiscal year, analysts anticipate that the firm will report earnings of ($0.90) per share, with EPS estimates ranging from ($1.09) to ($0.59). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Celldex Therapeutics.
CLDX has been the subject of a number of recent research reports. WBB Securities reissued a “buy” rating and issued a $10.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. HC Wainwright reissued a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Finally, BidaskClub cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, January 11th. Three analysts have rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Celldex Therapeutics presently has an average rating of “Hold” and a consensus price target of $7.05.
Shares of Celldex Therapeutics (NASDAQ CLDX) traded down $0.03 during trading on Tuesday, hitting $2.32. 1,116,660 shares of the stock were exchanged, compared to its average volume of 1,215,405. The company has a market capitalization of $315.49, a PE ratio of -2.30 and a beta of 2.57. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $3.94.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.